Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From X4 Pharmaceuticals
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022.
Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.
Colorado-based Bolder recently announced the global launch of the CoolSeal vessel sealing platform, which will complement Hologic’s obstetrical/gynecological surgery product line.
Following the purchase of Mobidiag, Hologic has aggressively launched the Novodiag platform across Europe in a bid to dominate the local molecular diagnostics market.
- Chiral Chemistry
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
Drug Discovery Tools
- Molecular Diversity